WO2002019985A3 - Methods for inhibiting decrease in transdermal drug flux by inhibition of pathway closure - Google Patents

Methods for inhibiting decrease in transdermal drug flux by inhibition of pathway closure Download PDF

Info

Publication number
WO2002019985A3
WO2002019985A3 PCT/US2001/027551 US0127551W WO0219985A3 WO 2002019985 A3 WO2002019985 A3 WO 2002019985A3 US 0127551 W US0127551 W US 0127551W WO 0219985 A3 WO0219985 A3 WO 0219985A3
Authority
WO
WIPO (PCT)
Prior art keywords
agent
inhibiting
inhibition
decrease
methods
Prior art date
Application number
PCT/US2001/027551
Other languages
French (fr)
Other versions
WO2002019985A2 (en
Inventor
Weiqi Lin
Michel J N Cormier
Peter E Daddona
Juanita A Johnson
James A Matriano
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to MXPA03002122A priority Critical patent/MXPA03002122A/en
Priority to NZ524646A priority patent/NZ524646A/en
Application filed by Alza Corp filed Critical Alza Corp
Priority to KR1020037003472A priority patent/KR100764699B1/en
Priority to DE60129585T priority patent/DE60129585T2/en
Priority to EEP200300095A priority patent/EE200300095A/en
Priority to IL15481101A priority patent/IL154811A0/en
Priority to AU8877401A priority patent/AU8877401A/en
Priority to AU2001288774A priority patent/AU2001288774B2/en
Priority to JP2002524470A priority patent/JP5507030B2/en
Priority to BR0113749-2A priority patent/BR0113749A/en
Priority to DK01968531T priority patent/DK1335711T3/en
Priority to CA002422200A priority patent/CA2422200A1/en
Priority to EP01968531A priority patent/EP1335711B1/en
Publication of WO2002019985A2 publication Critical patent/WO2002019985A2/en
Publication of WO2002019985A3 publication Critical patent/WO2002019985A3/en
Priority to NO20031071A priority patent/NO20031071L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches

Abstract

This invention relates to a method for inhibiting a decrease in the transdermal flux of an agent that is being transdermally delivered or sampled over a prolonged period of time wherein the delivery or sampling involves disrupting at least the stratum corneum layer of the skin to form pathways through which the agent passes. The desired result is achieved by co-delivering or co-sampling the agent with an amount of at least one anti-healing agent wherein the amount of the anti-healing agent is effective in inhibiting a decrease in the agent transdermal flux compared to when the delivery or sampling of the agent is done under substantially identical conditions except in the absence of the anti-healing agent(s).
PCT/US2001/027551 2000-09-08 2001-09-06 Methods for inhibiting decrease in transdermal drug flux by inhibition of pathway closure WO2002019985A2 (en)

Priority Applications (14)

Application Number Priority Date Filing Date Title
JP2002524470A JP5507030B2 (en) 2000-09-08 2001-09-06 Methods for suppressing reduction in transdermal drug flow by inhibiting pathway closure
AU2001288774A AU2001288774B2 (en) 2000-09-08 2001-09-06 Methods for inhibiting decrease in transdermal drug flux by inhibition of pathway closure
KR1020037003472A KR100764699B1 (en) 2000-09-08 2001-09-06 Methods for inhibiting decrease in transdermal drug flux by inhibition of pathway closure
NZ524646A NZ524646A (en) 2000-09-08 2001-09-06 Methods for inhibiting decrease in transdermal drug flux by inhibition of pathway closure
EEP200300095A EE200300095A (en) 2000-09-08 2001-09-06 Methods of Inhibiting Decrease in Drug Transdermal Transportation by Inhibiting Canal Closure
IL15481101A IL154811A0 (en) 2000-09-08 2001-09-06 Methods for inhibiting decrease in transdermal drug flux by inhibition of pathway closure
BR0113749-2A BR0113749A (en) 2000-09-08 2001-09-06 Methods to inhibit decrease in transdermal drug flow by inhibiting pathway closure
MXPA03002122A MXPA03002122A (en) 2000-09-08 2001-09-06 Methods for inhibiting decrease in transdermal drug flux by inhibition of pathway closure.
DE60129585T DE60129585T2 (en) 2000-09-08 2001-09-06 TRANSDERMALE DEVICE
AU8877401A AU8877401A (en) 2000-09-08 2001-09-06 Methods for inhibiting decrease in transdermal drug flux by inhibition of pathway closure
DK01968531T DK1335711T3 (en) 2000-09-08 2001-09-06 Transdermal device
CA002422200A CA2422200A1 (en) 2000-09-08 2001-09-06 Methods for inhibiting decrease in transdermal drug flux by inhibition of pathway closure
EP01968531A EP1335711B1 (en) 2000-09-08 2001-09-06 Transdermal device
NO20031071A NO20031071L (en) 2000-09-08 2003-03-07 Method of Inhibiting Decrease in Transdermal Drug Flow Through Inhibition by Closing the Reaction Pathway

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23116000P 2000-09-08 2000-09-08
US60/231,160 2000-09-08

Publications (2)

Publication Number Publication Date
WO2002019985A2 WO2002019985A2 (en) 2002-03-14
WO2002019985A3 true WO2002019985A3 (en) 2002-09-06

Family

ID=22867983

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/027551 WO2002019985A2 (en) 2000-09-08 2001-09-06 Methods for inhibiting decrease in transdermal drug flux by inhibition of pathway closure

Country Status (24)

Country Link
US (1) US7438926B2 (en)
EP (1) EP1335711B1 (en)
JP (2) JP5507030B2 (en)
KR (1) KR100764699B1 (en)
CN (1) CN100421653C (en)
AT (1) ATE367805T1 (en)
AU (2) AU2001288774B2 (en)
BR (1) BR0113749A (en)
CA (1) CA2422200A1 (en)
CZ (1) CZ2003687A3 (en)
DE (1) DE60129585T2 (en)
DK (1) DK1335711T3 (en)
EE (1) EE200300095A (en)
ES (1) ES2290166T3 (en)
IL (1) IL154811A0 (en)
MA (1) MA25958A1 (en)
MX (1) MXPA03002122A (en)
NO (1) NO20031071L (en)
NZ (1) NZ524646A (en)
PL (1) PL365603A1 (en)
PT (1) PT1335711E (en)
RU (1) RU2272618C2 (en)
WO (1) WO2002019985A2 (en)
ZA (1) ZA200302700B (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001288774B2 (en) * 2000-09-08 2006-06-29 Alza Corporation Methods for inhibiting decrease in transdermal drug flux by inhibition of pathway closure
EP1333880B1 (en) * 2000-10-26 2009-04-15 Alza Corporation Transdermal drug delivery devices having coated microprotrusions
US6908453B2 (en) * 2002-01-15 2005-06-21 3M Innovative Properties Company Microneedle devices and methods of manufacture
MXPA06000281A (en) 2003-06-30 2006-07-03 Johnson & Johnson Formulations for coated microprojections containing non-volatile counterions.
AR044985A1 (en) * 2003-07-02 2005-10-12 Alza Corp IMMUNIZATION METHOD AND PATCH BY MICROPROJECTION PROVISION
WO2005020912A2 (en) 2003-08-25 2005-03-10 3M Innovative Properties Company Delivery of immune response modifier compounds
CA2542874A1 (en) * 2003-10-23 2005-05-12 Alza Corporation Compositions of stabilized dna for coating microprojections
WO2005042054A2 (en) 2003-10-24 2005-05-12 Alza Corporation Pretreatment method and system for enhancing transdermal drug delivery
CN100548228C (en) * 2003-11-13 2009-10-14 阿尔扎公司 The compositions and the device that are used for transdermal delivery
AU2005232541A1 (en) 2004-04-01 2005-10-27 Alza Corporation Apparatus and method for transdermal delivery of influenza vaccine
CA2562642A1 (en) * 2004-04-13 2005-11-03 Alza Corporation Apparatus and method for transdermal delivery of multiple vaccines
JP2007532645A (en) * 2004-04-13 2007-11-15 アルザ コーポレイション Devices and methods for transdermal delivery systems of drugs based on fentanyl
MX2007001667A (en) * 2004-08-11 2007-10-02 Johnson & Johnson Apparatus and method for transdermal delivery of natriuretic peptides.
JP5015787B2 (en) 2004-11-18 2012-08-29 スリーエム イノベイティブ プロパティズ カンパニー Contact coating method of microneedle array
WO2006055799A1 (en) * 2004-11-18 2006-05-26 3M Innovative Properties Company Masking method for coating a microneedle array
US8057842B2 (en) 2004-11-18 2011-11-15 3M Innovative Properties Company Method of contact coating a microneedle array
AU2006214236A1 (en) * 2005-02-16 2006-08-24 Alza Corporation Apparatus and method for transdermal delivery of erythropoetin-based agents
US20060253078A1 (en) * 2005-04-25 2006-11-09 Wu Jeffrey M Method of treating skin disorders with stratum corneum piercing device
US20070270738A1 (en) * 2005-04-25 2007-11-22 Wu Jeffrey M Method of treating ACNE with stratum corneum piercing patch
EP1904158B1 (en) 2005-06-24 2013-07-24 3M Innovative Properties Company Collapsible patch with microneedle array
US20070078414A1 (en) * 2005-08-05 2007-04-05 Mcallister Devin V Methods and devices for delivering agents across biological barriers
WO2007061964A1 (en) * 2005-11-18 2007-05-31 3M Innovative Properties Company Methods for coating microneedles
EP2018835B1 (en) * 2007-07-09 2014-03-05 Augustinus Bader Agent-eluting plaster
US8617487B2 (en) 2009-03-25 2013-12-31 Venture Lending & Leasing Vi, Inc. Saliva sample collection systems
CN102470118B (en) * 2009-07-24 2014-12-17 21世纪国际新技术株式会社 External preparation containing nsaids and method for producing the external preparation
EP2818159A1 (en) 2013-06-25 2014-12-31 LTS LOHMANN Therapie-Systeme AG Device having transdermal therapeutic system, positioning and penetration aid
US9987361B1 (en) * 2014-12-29 2018-06-05 Noven Pharmaceuticals, Inc. Compositions and method for sustained drug delivery by active transdermal technology
DE102017126501A1 (en) 2017-11-10 2019-05-16 Lts Lohmann Therapie-Systeme Ag Micro needle system for the application of a hepatitis vaccine
US20190231925A1 (en) * 2018-01-31 2019-08-01 Changchun Ja Biotech. Co., Ltd. Heparin sodium supported hydrogel sustained-release paster

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996017648A1 (en) * 1994-12-09 1996-06-13 Novartis Ag Transdermal system
WO1997048440A1 (en) * 1996-06-18 1997-12-24 Alza Corporation Device for enhancing transdermal agent delivery or sampling
WO2000074763A2 (en) * 1999-06-04 2000-12-14 Georgia Tech Research Corporation Devices and methods for enhanced microneedle penetration of biological barriers
WO2001041864A1 (en) * 1999-12-10 2001-06-14 Alza Corporation Skin treatment apparatus for sustained transdermal drug delivery

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE25637E (en) 1964-09-08 Means for vaccinating
US3964482A (en) 1971-05-17 1976-06-22 Alza Corporation Drug delivery device
BE795384A (en) 1972-02-14 1973-08-13 Ici Ltd DRESSINGS
EP0429842B1 (en) 1989-10-27 1996-08-28 Korea Research Institute Of Chemical Technology Device for the transdermal administration of protein or peptide drug
US5279544A (en) 1990-12-13 1994-01-18 Sil Medics Ltd. Transdermal or interdermal drug delivery devices
IL109037A (en) * 1993-03-19 1999-01-26 Cellegy Pharma Inc Compositions for inducing phase separation of epithelial lipid bilayers and preparation of said compositions
US5458140A (en) 1993-11-15 1995-10-17 Non-Invasive Monitoring Company (Nimco) Enhancement of transdermal monitoring applications with ultrasound and chemical enhancers
US5885211A (en) 1993-11-15 1999-03-23 Spectrix, Inc. Microporation of human skin for monitoring the concentration of an analyte
AU5740496A (en) 1995-05-22 1996-12-11 General Hospital Corporation, The Micromechanical device and method for enhancing delivery of compounds through the skin
WO1996037256A1 (en) 1995-05-22 1996-11-28 Silicon Microdevices, Inc. Micromechanical patch for enhancing the delivery of compounds through the skin
DE19525607A1 (en) 1995-07-14 1997-01-16 Boehringer Ingelheim Kg Transcorneal drug delivery system
US5902603A (en) * 1995-09-14 1999-05-11 Cygnus, Inc. Polyurethane hydrogel drug reservoirs for use in transdermal drug delivery systems, and associated methods of manufacture and use
DE19541260A1 (en) * 1995-11-06 1997-05-07 Lohmann Therapie Syst Lts Therapeutic preparation for transdermal application of active ingredients through the skin
US6183434B1 (en) 1996-07-03 2001-02-06 Spectrx, Inc. Multiple mechanical microporation of skin or mucosa
ATE231015T1 (en) 1996-09-17 2003-02-15 Deka Products Lp SYSTEM FOR DELIVERY OF MEDICATION THROUGH TRANSPORT
WO1998028037A1 (en) 1996-12-20 1998-07-02 Alza Corporation Device and method for enhancing transdermal agent flux
DE19654391A1 (en) 1996-12-27 1998-07-02 Basf Ag Catalyst for the selective production of propylene from propane
ES2289192T3 (en) * 1996-12-31 2008-02-01 Altea Therapeutics Corporation TISSUE MICROPORATION FOR SUPPLY OF BIOACTIVE AGENTS.
US6918901B1 (en) * 1997-12-10 2005-07-19 Felix Theeuwes Device and method for enhancing transdermal agent flux
DK1037686T3 (en) * 1997-12-11 2006-01-02 Alza Corp Apparatus for enhancing transdermal flow of agents
ATE221400T1 (en) * 1997-12-11 2002-08-15 Alza Corp DEVICE FOR INCREASE THE TRANSDERMAL FLOW OF ACTIVE INGREDIENTS
PT1037687E (en) 1997-12-11 2008-12-17 Alza Corp Device for enhancing transdermal agent flux
US6022316A (en) 1998-03-06 2000-02-08 Spectrx, Inc. Apparatus and method for electroporation of microporated tissue for enhancing flux rates for monitoring and delivery applications
AU767122B2 (en) 1998-06-10 2003-10-30 Georgia Tech Research Corporation Microneedle devices and methods of manufacture and use thereof
EP1180053A4 (en) * 1999-05-17 2006-11-08 Kevin S Marchitto Remote and local controlled delivery of pharmaceutical compounds using electromagnetic energy
DE60024312T2 (en) * 1999-12-10 2006-08-17 Alza Corp., Mountain View Transdermal drug delivery of macromolecular agents and device therefor
AU2001288774B2 (en) * 2000-09-08 2006-06-29 Alza Corporation Methods for inhibiting decrease in transdermal drug flux by inhibition of pathway closure
EP1333880B1 (en) * 2000-10-26 2009-04-15 Alza Corporation Transdermal drug delivery devices having coated microprotrusions
WO2004030743A2 (en) * 2002-09-30 2004-04-15 Alza Corporation Drug delivery device having coated microprojections incorporating vasoconstrictors

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996017648A1 (en) * 1994-12-09 1996-06-13 Novartis Ag Transdermal system
WO1997048440A1 (en) * 1996-06-18 1997-12-24 Alza Corporation Device for enhancing transdermal agent delivery or sampling
WO2000074763A2 (en) * 1999-06-04 2000-12-14 Georgia Tech Research Corporation Devices and methods for enhanced microneedle penetration of biological barriers
WO2001041864A1 (en) * 1999-12-10 2001-06-14 Alza Corporation Skin treatment apparatus for sustained transdermal drug delivery

Also Published As

Publication number Publication date
DK1335711T3 (en) 2007-11-26
JP2004508319A (en) 2004-03-18
EP1335711B1 (en) 2007-07-25
KR20030074595A (en) 2003-09-19
KR100764699B1 (en) 2007-10-08
DE60129585D1 (en) 2007-09-06
RU2272618C2 (en) 2006-03-27
MXPA03002122A (en) 2004-09-10
ES2290166T3 (en) 2008-02-16
IL154811A0 (en) 2003-10-31
ATE367805T1 (en) 2007-08-15
CA2422200A1 (en) 2002-03-14
CZ2003687A3 (en) 2004-01-14
NO20031071L (en) 2003-05-06
BR0113749A (en) 2004-06-22
CN100421653C (en) 2008-10-01
NZ524646A (en) 2004-10-29
AU8877401A (en) 2002-03-22
NO20031071D0 (en) 2003-03-07
PT1335711E (en) 2007-09-05
MA25958A1 (en) 2003-12-31
PL365603A1 (en) 2005-01-10
ZA200302700B (en) 2004-08-13
US20020102292A1 (en) 2002-08-01
US7438926B2 (en) 2008-10-21
JP2013256500A (en) 2013-12-26
EE200300095A (en) 2005-02-15
WO2002019985A2 (en) 2002-03-14
JP5507030B2 (en) 2014-05-28
DE60129585T2 (en) 2008-04-17
AU2001288774B2 (en) 2006-06-29
CN1473037A (en) 2004-02-04
EP1335711A2 (en) 2003-08-20

Similar Documents

Publication Publication Date Title
WO2002019985A3 (en) Methods for inhibiting decrease in transdermal drug flux by inhibition of pathway closure
WO2004006906A3 (en) Methods for the treatment of neoplasms
WO2006047392A3 (en) Nicotinic-opioid synergy for analgesia
WO2003032914A3 (en) Methods for treating substance abuse with cholinesterase inhibitors
IE893455L (en) Dosage form having reduced abuse potential
WO2005048942A3 (en) Combination therapy comprising a cox-2 inhibitor and an antineoplastic agent
WO2005018677A3 (en) Use of combination of an epidermal growth factor receptor kinase inhibitor and cytotoxic agents for treatment and inhibition of cancer
HK1068545A1 (en) Transdermal patch for administering fentanyl
WO2004110490A3 (en) Use of vegf inhibitors for tumor regression
WO2007149782A3 (en) Selective inhibitors for transferases
WO2005044139A3 (en) Method and apparatus for reducing the incidence of tobacco use
WO2011139595A3 (en) Elongated biodegradable depot for sustained drug release to treat chronic pelvic pain
WO2001068125A3 (en) Methods and compositions for the treatment and prevention of erectile dysfunction
WO2003092606A3 (en) Cholinesterase inhibitors to prevent injuries caused by chemicals
WO2001087343A3 (en) Combination therapy using cox-2 selective inhibitor and thromboxane inhibitor and compositions therefor
WO2007143185A3 (en) Transdermal treatment of tendinopathy using glyceryl trinitrite
WO2005037347A3 (en) Treatment of overuse tendinopathy using transdermal nitric oxide-generating agents
WO2000023062A3 (en) Irrigation solution and method for inhibition of pain and inflammation
WO2003032910A3 (en) Carbinols for the treatment of neuropathic dysfunction
WO2004007676A3 (en) Combination therapy for the treatment of neoplasms
WO2007103190A3 (en) Transdermal treatment of tendinop athy using no donor
WO2006060759A3 (en) A sterically stabilized liposome and triamcinolone composition for treating the respiratory tract of a mammal
WO2003034999A3 (en) Medication and method for remediating existing scars through transdermal topical delivery of calcium channel blockers
WO2000025745A3 (en) Irrigation solution and method for inhibition of pain and inflammation
WO2001000191A3 (en) Use of fosphenytion for the treatment of acute neuropathic pain

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 154811

Country of ref document: IL

Ref document number: PV2003-687

Country of ref document: CZ

Ref document number: 2001288774

Country of ref document: AU

Ref document number: 2422200

Country of ref document: CA

Ref document number: 289/KOLNP/2003

Country of ref document: IN

Ref document number: 1200300231

Country of ref document: VN

WWE Wipo information: entry into national phase

Ref document number: 1020037003472

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: PA/a/2003/002122

Country of ref document: MX

Ref document number: 524646

Country of ref document: NZ

Ref document number: 2002524470

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2001968531

Country of ref document: EP

Ref document number: 2003/02700

Country of ref document: ZA

Ref document number: 200302700

Country of ref document: ZA

ENP Entry into the national phase

Ref document number: 2003109743

Country of ref document: RU

Kind code of ref document: A

Ref country code: RU

Ref document number: RU A

WWE Wipo information: entry into national phase

Ref document number: 018185835

Country of ref document: CN

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2001968531

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020037003472

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: PV2003-687

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 524646

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 524646

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 2001968531

Country of ref document: EP